- Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
- The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
- Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
- This announcement follows a successful clinical trial conducted by the University of Western Australia
- Zelira is on track to launch five new products across global markets in 2020
- Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Zelira Therapeutics: Launches Zenivol in Australia
- Advertisement -
